Fungal cell membrane and intracellular iron-dependent metabolic processes

The fungal cell membrane and intracellular iron-dependent metabolic processes represent a composite therapeutic target for broad-spectrum antifungal agents like ciclopirox (PubChem, CID 2749). This target involves the chelation of polyvalent cations, specifically Fe3+ and Al3+, which are vital cofactors for various fungal enzymes (DrugBank, DB01188). Inhibition of these iron-dependent enzymes, such as cytochromes, catalase, and peroxidase, disrupts mitochondrial respiration and the cell's ability to detoxify reactive oxygen species (NCBI, PMC3171650). Additionally, the drug-target interaction alters the permeability and transport functions of the fungal plasma membrane, leading to the depletion of essential intracellular substrates (FDA, Penlac Label). This dual mechanism of action—targeting both metabolic enzymes and structural membrane integrity—makes it effective against a wide range of dermatophytes, yeasts, and molds (StatPearls, NBK557513). Clinical application is primarily focused on treating superficial mycoses, where the disruption of these processes leads to fungicidal activity (PubMed, 10928586). Unlike many antifungals that target ergosterol biosynthesis, this mechanism provides a distinct pathway that reduces the likelihood of cross-resistance (NCBI, PMC3171650).

Other names

Fungal iron-dependent enzymesFungal plasma membraneMetal-dependent fungal metabolic pathwaysCiclopirox target system

Drugs targeting these processes act by chelating trivalent cations (Fe3+ and Al3+), which inactivates essential metal-dependent enzymes involved in mitochondrial electron transport and peroxide degradation, while simultaneously disrupting the fungal cell membrane to impair nutrient uptake (DrugBank, DB01188; PubChem, CID 2749).